Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by waves1on Aug 04, 2022 3:36pm

92 Views

Post# 34872011

ACC invitation is great acknowledgment of AGN's work

AGN being invited to present the results from its Phase 2a study of NP-120 for IPF and Chronic Cough at the American Cough Conference in June 2023 is a significant acknowledgment of their work within the field.

Held every two years, the conference is the worlds leading educational meeting for health care professionals involved in the research and management of patients with coughs.

A conference chair highlighted their excitement at AGN's attendance as they believe the receptor to be a fascinating target as it would be a first-in-class treatment if successful.

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-invited-present-phase-110700114.html

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market